文献速递呼吸衰竭与机械通气消化、代谢与肾脏急症

西罗莫司对淋巴管肌瘤病患者血清血管内皮生长因子D水平的长期影响

Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
PubMed 文献 · Chest · 2017-05-19
一句话结论西罗莫司治疗淋巴管肌瘤病可长期稳定肺功能并持续降低升高的血清VEGF-D水平,但VEGF-D下降幅度与肺功能获益无关联。

该研究纳入25例淋巴管肌瘤病(LAM)患者,在自西罗莫司治疗前及治疗期间测量血清VEGF-D水平、肺功能和淋巴管病变范围,以评估VEGF-D下降是否随时间持续及与肺功能、淋巴管病变的平行变化。结果显示,西罗莫司治疗4.5±1.6年期间稳定了FEV1和一氧化碳弥散量(Dlco),淋巴管病变消退,血管平滑肌脂肪瘤体积缩小,VEGF-D水平从3,720±3,020 pg/mL降至945±591 pg/mL(P < .0001)。FEV1占预计值百分比和Dlco占预计值百分比的年变化分别从-7.4%±1.4%降至-0.3%±0.5%(P < .001)和从-6.4%±0.9%降至-0.4%±0.5%(P < .001)。较低的VEGF-D水平与西罗莫司治疗相关(P < .001),但VEGF-D下降幅度与FEV1、Dlco变化之间无显著关系。有淋巴管病变的患者较无淋巴管病变者血清VEGF-D水平更高、VEGF-D下降幅度更大,且西罗莫司治疗期间肺功能长期持续改善更好。

要点

  • 25例LAM患者西罗莫司治疗4.5±1.6年,FEV1占预计值百分比年变化从-7.4%±1.4%降至-0.3%±0.5%(P < .001),Dlco占预计值百分比年变化从-6.4%±0.9%降至-0.4%±0.5%(P < .001)。
  • 西罗莫司治疗使血清VEGF-D从3,720±3,020 pg/mL降至945±591 pg/mL(P < .0001),且下降持续存在。
  • VEGF-D下降幅度与FEV1、Dlco变化无显著关系,不能以VEGF-D降幅预测肺功能获益。
  • 有淋巴管病变者较无淋巴管病变者血清VEGF-D更高、降幅更大,且肺功能长期持续改善更好。
  • 西罗莫司治疗期间淋巴管病变消退,血管平滑肌脂肪瘤体积缩小。

适用人群与场景

  • 25例淋巴管肌瘤病(LAM)患者,在西罗莫司治疗前及治疗期间进行评价。

研究设计与关键结果

  • 研究类型为治疗前后自身对照的观察性评价,纳入25例LAM患者,测量西罗莫司治疗前及治疗期间的VEGF-D水平、肺功能和淋巴管病变范围。
  • 西罗莫司治疗4.5±1.6年期间稳定FEV1和Dlco,淋巴管病变消退,血管平滑肌脂肪瘤体积缩小,VEGF-D水平从3,720±3,020 pg/mL降至945±591 pg/mL(P < .0001)。
  • FEV1占预计值百分比的年变化从-7.4%±1.4%降至-0.3%±0.5%(P < .001),Dlco占预计值百分比的年变化从-6.4%±0.9%降至-0.4%±0.5%(P < .001)。
  • 较低的VEGF-D水平与西罗莫司治疗相关(P < .001),但VEGF-D下降幅度与FEV1、Dlco变化之间无显著关系。
  • 有淋巴管病变者较无淋巴管病变者血清VEGF-D水平更高、VEGF-D下降幅度更大,且西罗莫司治疗期间肺功能长期持续改善更好。

证据类型、等级与局限

  • 证据类型:治疗前后自身对照的观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于LAM患者,西罗莫司治疗可长期稳定肺功能并持续降低升高的血清VEGF-D水平,但VEGF-D下降幅度不能用于预测肺功能获益。
  • 有淋巴管病变的LAM患者可能从西罗莫司治疗中获得更好的长期肺功能持续改善。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sirolimus reduces serum levels of vascular endothelial growth factor D (VEGF-D); the size of chylous effusions, lymphangioleiomyomas, and angiomyolipomas; and stabilizes lung function in patients with lymphangioleiomyomatosis (LAM).

METHODS: To determine whether reductions in VEGF-D levels are sustained over time, as well as parallel changes in lung function and lymphatic disease, we evaluated 25 patients with LAM and measured VEGF-D levels, lung function, and extent of lymphatic disease before and during sirolimus therapy.

RESULTS: Treatment with sirolimus stabilized FEV1 and diffusion capacity for carbon monoxide (Dlco) over a period of 4.5 ± 1.6 years, caused resolution of lymphatic disease, and reduced the size of angiomyolipomas and VEGF-D levels (3,720 ± 3,020 pg/mL to 945 ± 591 pg/mL; P < .0001). Yearly changes in FEV1 % predicted and Dlco % predicted were reduced from -7.4% ± 1.4% to -0.3% ± 0.5% (P < .001) and -6.4% ± 0.9% to -0.4% ± 0.5% (P < .001), respectively. Lower VEGF-D levels correlated with sirolimus therapy (P < .001), but no significant relationship was observed between reduction in VEGF-D levels and FEV1 and Dlco during sirolimus therapy. The magnitude of VEGF-D decline was not related to the effect on lung function. Patients with lymphatic disease had higher serum VEGF-D levels, a greater reduction in VEGF-D levels, and better long-term sustained improvement in lung function during sirolimus therapy than did those without lymphatic disease.

CONCLUSIONS: Sirolimus therapy stabilizes lung function over many years of therapy while producing a sustained reduction in VEGF-D levels in patients with elevated levels preceding therapy. An association was not demonstrated between the magnitude of VEGF-D decline and the beneficial effect of sirolimus on lung function. Persistent improvement in lung function was observed in patients with lymphatic disease.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis. Chest. 2017. PMID: 28533049. doi:10.1016/j.chest.2017.05.012

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。